References
Abadias M, Escriche M, Vaque A, Sust M, & Encina G (2013). Safety, tolerability and pharmacokinetics of single and multiple doses of a novel sigma-1 receptor antagonist in three randomized phase I studies. Br J Clin Pharmacol 75: 103-117.
Abbas H, Borde P, Willars GB, Ferry DR, & Safrany ST (2020). Hazards of using masking protocols when performing ligand binding assays: Lessons from the sigma-1 and sigma-2 receptors. Front Pharmacol 11:309.
Oxaliplatin 5mg/mL summary of Product Characteristics.[Online] Available from https://www.medicines.org.uk/emc/product/6088/smpc. [Accessed: January 2021].
Alon A, Schmidt HR, Wood MD, Sahn JJ, Martin SF, & Kruse AC (2017). Identification of the gene that codes for the sigma-2 receptor. Proc Natl Acad Sci U S A 114: 7160-7165.
Bozdogan H (1987). Model selection and Akaike’s Information Criterion (AIC): The gerneal theory and its analytical extensions. Psychometrika 52: 345-370.
Bravo-Caparros I, Perazzoli G, Yeste S, Cikes D, Baeyens JM, Cobos EJ, et al. (2019). Sigma-1 receptor inhibition reduces neuropathic pain induced by partial sciatic nerve transection in mice by opioid-dependent and -independent mechanisms. Front Pharmacol 10: 613.
Bruna J, Videla S, Argyriou AA, Velasco R, Villoria J, Santos C, et al. (2018). Efficacy of a novel sigma-1 receptor antagonist for oxaliplatin-induced neuropathy: A randomized, double-blind, placebo-controlled Phase IIa clinical trial. Neurotherapeutics 15: 178-189.
Brust P, Deuther-Conrad W, Lehmkuhl K, Jia H, & Wunsch B (2014). Molecular imaging of sigma-1 receptors in vivo: current status and perspectives. Curr Med Chem 21: 35-69.
Cipriano PW, Lee SW, Yoon D, Shen B, Tawfik VL, Curtin CM, et al.(2018). Successful treatment of chronic knee pain following localization by a sigma-1 receptor radioligand and PET/MRI: a case report. J Pain Res 11: 2353-2357.
Colloca L, Ludman T, Bouhassira D, Baron R, Dickenson AH, Yarnitsky D, et al. (2017). Neuropathic pain. Nat Rev Dis Primers 3: 17002.
Cunningham VJ, Rabiner EA, Slifstein M, Laruelle M, & Gunn RN (2010). Measuring drug occupancy in the absence of a reference region: the Lassen plot re-visited. J Cereb Blood Flow Metab 30: 46-50.
Curtis MJ, Alexander S, Cirino G, Docherty JR, George CH, Giembycz MA, et al. (2018). Experimental design and analysis and their reporting II: updated and simplified guidance for authors and peer reviewers. Br J Pharmacol 175: 987-993.
Davis MP (2015). Sigma-1 receptors and animal studies centered on pain and analgesia. Expert Opin Drug Discov 10: 885-900.
Clinical trial results: An exploratory, randomized, double blind, placebo controlled, parallel groups Phase II clinical trial to evaluate the efficacy and safety of E-52862 (400 mg) by oral route, in patients with post-surgical neuropathic pain. [Online] Available from https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-000402-30/results. [Accessed: January 2021].
Grabner G, Janke AL, Budge MM, Smith D, Pruessner J, & Collins DL (2006). Symmetric atlasing and model based segmentation: an application to the hippocampus in older adults. Med Image Comput Comput Assist Interv 9: 58-66.
Gris G, Portillo-Salido E, Aubel B, Darbaky Y, Deseure K, Vela JM, et al. (2016). The selective sigma-1 receptor antagonist E-52862 attenuates neuropathic pain of different aetiology in rats. Sci Rep 6: 24591.
Hou S, Huh B, Kim HK, Kim K-H, & Abdi S (2018). Treatment of chemotherpy-induced peripheral neuropathy: Systematic review and recommendations. Pain Physician 21: 571-592.
Ichise M, Toyama H, Innis RB, & Carson RE (2002). Strategies to improve neuroreceptor parameter estimation by linear regression analysis. J Cereb Blood Flow Metab 22: 1271-1281.
Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, et al. (2007). Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 27:1533-1539.
Ishikawa M, Ishiwata K, Ishii K, Kimura Y, Sakata M, Naganawa M, et al. (2007). High occupancy of sigma-1 receptors in the human brain after single oral administration of fluvoxamine: a positron emission tomography study using [11C]SA4503. Biol Psychiatry 62:878-883.
Ishiwata K, Oda K, Sakata M, Kimura Y, Kawamura K, Oda K, et al.(2006). A feasibility study of [11C]SA4503-PET for evaluating sigmal receptor occupancy by neuroleptics: the binding of haloperidol to sigma1 and dopamine D2-like receptors. Ann Nucl Med 20: 569-573.
Kawamura K, Ishiwata K, Tajima H, Ishii S, Matsuno K, Homma Y, et al. (2000). In vivo evaluation of [(11)C]SA4503 as a PET ligand for mapping CNS sigma(1) receptors. Nucl Med Biol 27:255-261.
Lever JR, Gustafson JL, Xu R, Allmon RL, & Lever SZ (2006). Sigma-1 and sigma-2 receptor binding affinity and selectivity of SA4503 and fluoroethyl SA4503. Synapse 59: 350-358.
Mansur A, Rabiner EA, Comley RA, Lewis Y, Middleton LT, Huiban M, et al. (2019). Characterization of 3 PET tracers for quantification of mitochondrial and synaptic function in healthy human brain: (18)F-BCPP-EF, (11)C-SA-4503, (11)C-UCB-J. J Nucl Med 61:96-103.
Matsuno K, Nakazawa M, Okamoto K, Kawashima Y, & Mita S (1996). Binding properties of SA4503, a novel and selective sigma 1 receptor agonist. Eur J Pharmacol 306: 271-279.
Morgan P, Van Der Graaf PH, Arrowsmith J, Feltner DE, Drummond KS, Wegner CD, et al. (2012). Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. Drug Discov Today 17: 419-424.
Nieto FR, Cendan CM, Canizares FJ, Cubero MA, Vela JM, Fernandez-Segura E, et al. (2014). Genetic inactivation and pharmacological blockade of sigma-1 receptors prevent paclitaxel-induced sensory-nerve mitochondrial abnormalities and neuropathic pain in mice. Mol Pain 10: 11.
Ortiz-Renteria M, Juarez-Contreras R, Gonzalez-Ramirez R, Islas LD, Sierra-Ramirez F, Llorente I, et al. (2018). TRPV1 channels and the progesterone receptor Sig-1R interact to regulate pain. Proc Natl Acad Sci U S A 115: E1657-E1666.
Pabba M, Wong AY, Ahlskog N, Hristova E, Biscaro D, Nassrallah W, et al. (2014). NMDA receptors are upregulated and trafficked to the plasma membrane after sigma-1 receptor activation in the rat hippocampus. J Neurosci 34: 11325-11338.
Romero L, Zamanillo D, Nadal X, Sanchez-Arroyos R, Rivera-Arconada I, Dordal A, et al. (2012). Pharmacological properties of S1RA, a new sigma-1 receptor antagonist that inhibits neuropathic pain and activity-induced spinal sensitization. Br J Pharmacol 166:2289-2306.
Saif MW, & Reardon J (2005). Management of oxaliplatin-induced peripheral neuropathy. Ther Clin Risk Manag 1: 249-258.
Sakata M, Kimura Y, Naganawa M, Oda K, Ishii K, Chihara K, et al.(2007). Mapping of human cerebral sigma1 receptors using positron emission tomography and [11C]SA4503. Neuroimage 35: 1-8.
Sanchez-Fernandez C, Entrena JM, Baeyens JM, & Cobos EJ (2017). Sigma-1 receptor antagonists: A new class of neuromodulatory analgesics. Adv Exp Med Biol 964: 109-132.
Stewart JM (2004). Chronic orthostatic intolerance and the postural tachycardia syndrome (POTS). J Pediatr 145: 725-730.
Tziortzi AC, Searle GE, Tzimopoulou S, Salinas C, Beaver JD, Jenkinson M, et al. (2011). Imaging dopamine receptors in humans with [11C]-(+)-PHNO: dissection of D3 signal and anatomy. Neuroimage 54: 264-277.
Vela JM, Merlos M, & Almansa C (2015). Investigational sigma-1 receptor antagonists for the treatment of pain. Expert Opin Investig Drugs 24: 883-896.
Zajaczkowska R, Kocot-Kepska M, Leppert W, Wrzosek A, Mika J, & Wordliczek J (2019). Mechanisms of chemotherapy-induced peripheral neuropathy. Int J Mol Sci 20: 1451.
Table 1: Pharmacokinetic–σ-1 brain receptor occupancy models